Inosine Pranobex is the first antiviralagent used to treat SSPE.

Empowering the Future, Healing the Present:
IsoJol offers solid Resolve Against Subacute Sclerosing
Panencephalitis (SSPE)
Know More

What is About IsoJol ?

Inosine Pranobex is the first antiviral agent used to treat SSPE. It exerts both
antiviral and immunostimulatory effects.
The Inosine Pranobex (ISOP)

CARES

61% Positive
Success Rate
for SSPE Patients

Potentially reshaping treatment
with groundbreaking revelation

In a groundbreaking revelation, it has been found that within the age group of 8-year-old children afflicted with SSPE, a staggering 61% experienced enhanced survival when treated with Inosine Pranobex . This significant finding underscores the pivotal role of Inosine Pranobex in bolstering survival rates specifically among young patients grappling with this devastating neurological condition. Such outcomes herald a new dawn of hope in pediatric healthcare, potentially reshaping treatment paradigms and offering renewed optimism for families facing the challenges of SSPE.

Optimized
Absorption
for SSPE Patients

Inosine Pranobex 500mg (ISOPRINOSINE) Bioavailability

Inosine Pranobex 500mg demonstrates favorable bioavailability, ensuring efficient absorption and distribution within the body, thereby optimizing its therapeutic efficacy.

Rapid Gastrointestinal Absorption

Peak Plasma
Concentrations
: 1-2 Hours

High Rate
Efficacy
for SSPE Patients

Inosine Pranobex Efficacy

Isoprinosine exhibits remarkable efficacy in managing various viral infections, including subacute sclerosing panencephalitis (SSPE), by exerting potent antiviral activity while also stimulating the immune system. This dual action enhances its effectiveness in combating viral pathogens and mitigating the progression of associated diseases, thereby offering hope and improved outcomes for patients.

  • Broad-Spectrum Action
  • Enhanced Immunity
  • Inhibits Viral Replication
Enhanced
Tolerability
for SSPE Patients

Balanced Tolerability

Majority of reported side effects fall within the "often" or "sometimes" categories, demonstrating it is generally well-tolerated in nature

Usually two major criteria plus one minor criterion are required for diagnosis of SSPE

© 2020 Jolly Healthcare. All rights reserved. In compliance with Drugs and Cosmetics Act, 1940 and Drugs and Cosmetics Rules, 1945, we don't process requests for Schedule X and other habit forming drugs.